Prostate Cancer Center Clinical Trials

The Louis Warschaw Prostate Cancer Center offers prostate cancer drugs that are being tested for their effectiveness. Depending on the patient's diagnosis, physicians may recommend that the patient enroll in a prostate cancer clinical trial. Clinical trials test new drugs, new combinations of drugs or new anticancer treatment strategies.

Upon enrolling in a prostate cancer clinical trial, a center research specialist will provide the patient with a written explanation of the proposed research treatment program, including risks and benefits. Patients will be required to sign a consent form that includes useful information on the specific form of cancer and the research treatment.

Research treatments offered by the Louis Warschaw Prostate Cancer Center are reviewed at a number of levels nationally and/or locally to protect the patients' rights and the scientific merit of the research. The Louis Warschaw Prostate Cancer Center will not enroll an individual in a clinical trial without their complete understanding, agreement, and consent and patients may withdraw at any time from a research treatment.

Click on the links below for information on contact, objective (study aims and relevance to patient care and scientific understanding), patient eligibility (required conditions for acceptance), schema (study procedures) and potential risks.

• Hormone-Refractory Prostate Cancer
• Other

For additional information about our clinical trials, please feel free to contact us.

Hormone-Refractory Prostate Cancer

A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study of CP-751,871 in Combination with Docetaxel/Prednisone in Chemotherapy-naïve (Arm A) and Docetaxel/Prednisone Refractory (Arm B) Patients with Hormone Insensitive Prostate Cancer
Industry Trial
Principal Investigator
David Agus, MD
IRB No. 8924

A Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer
Industry Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 10667

Phase Ib/II Evaluation of RAD001 with docetaxel and bevacizumab in Patients with Metastatic Androgen Independent Prostate Cancer
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 10405

A Phase II Study of Ixabepilone Prior to Surgery for High-Risk Localized Prostate Cancer
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 13963

Other

Prostate Patient Profiles Project (P4)
Institutional Trial
Principal Investigator
David Agus, MD
IRB No. 3979

Prostate Outcomes Project (POP). A Decision Outcomes Study of Patients with Newly Diagnosed Prostate Cancer and Treatment
Institutional Trial
Principal Investigator
Mahul Amin, MD
IRB No. 3840

Urine Markers to Determine Status in Prostate Cancer Patients Treated with Local Radiation
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 11986

Characterization of Circulating Tumor Cells of Metastatic Prostate Cancer Patients Using Gene Markers
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 11799

Characterization of Circulation Tumor Cells in Prostate Cancer Patients Prior to Surgery
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 16210